🚀 June’s AI-picked stocks soar, with Adobe +18.1% in 11 days. Don’t miss July’s upcoming picks.Unlock full list

Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use

Published 13/05/2024, 19:30
© Reuters.  Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use
JNJ
-

Benzinga - by Vandana Singh, Benzinga Editor.

Johnson & Johnson’s (NYSE:JNJ) medical device subsidiary is pulling its Megadyne Mega Soft Pediatric Patient Return Electrodes following reports of patient burns.

Ethicon’s Megadyne division recalled its Mega Soft and Mega 2000 return electrodes in June 2023. The soft reusable pads are used during electrosurgery.

The electrode aims to minimize the risk of electrical burns by ensuring the current flows safely through the patient’s body and back to the electrosurgical unit, preventing any concentration of electrical energy in one area of the body.

Previously labeled a Class I recall by the FDA, the agency’s most serious category, the move impacted 21,200 devices distributed over two years.

The FDA has said it collected reports of at least 63 injuries, including some third-degree burns, and zero patient deaths.

The recall was expanded in December 2023 to update certain devices’ product labeling and restrict their use to patients 12 years and older, covering around 9,500 units.

Because the pediatric pad is designed for patients between 0.8-50 pounds, predominantly patients under 12, the decision was made to discontinue and recall the 0840 pediatric pad product.

“A root cause investigation on the reports included testing which showed a combination of factors when present together may result in potential for thermal injuries,” J&J’s Megadyne said in its announcement.

“The combination of these conditions may be more likely when the pad is used with infants and small children,” the company said.

Between 2018 and today, there have been four reported injuries and no reports of death associated with this product.”

Price Action: JNJ shares are up 0.41% at $150.62 at last check Monday.

Photography Via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.